Alaunos Therapeutics
TCRTAlaunos Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel, orally administered small-molecule therapeutics for obesity and metabolic disorders.
Table of contents
Earnings
Next report
Aug 18, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Alaunos Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel, orally administered small-molecule therapeutics for obesity and metabolic disorders. The company's lead program utilizes a differentiated, non-hormonal mechanism of action to target weight loss and liver health, specifically addressing conditions like metabolic dysfunction-associated steatotic liver disease (MASLD). Alaunos recently pivoted from its legacy clinical-stage oncology cell therapy operations to focus exclusively on its metabolic pipeline.
Alaunos is an early-stage entrant in the obesity market, positioning itself as a non-hormonal alternative to established GLP-1 therapies.
Questions, answered.
- What is Alaunos Therapeutics's market cap?
- Alaunos Therapeutics (TCRT) has a market capitalization of $4.7M and trades on NASDAQ.
- Who are Alaunos Therapeutics's competitors?
- Alaunos Therapeutics's key competitors include Viking Therapeutics, Eli Lilly, Amgen, and others. These companies compete in similar markets and product categories.
- Who does Alaunos Therapeutics partner with?
- Alaunos Therapeutics's notable partners include The University of Texas MD Anderson Cancer Center, Precigen.
- Where is Alaunos Therapeutics headquartered?
- Alaunos Therapeutics is headquartered in United States of America and employs approximately 34 people. It has been publicly traded since 2005.